Role of IL-6 in shaping local immune milieus in the CNS

A07

IL-6 is increasingly identified as therapeutic target for a variety of inflammatory human diseases including Multiple Sclerosis. Due to the complexity of IL-6 directed interventions and differential responses of the distinct IL-6 signaling modalities to therapies, we now set out to investigate responses to IL-6 in the CNS in detail. We will assess the most relevant sources of IL-6 in the CNS, address the role of IL-6 signaling into conventional T cells and Foxp3+ Treg cells in the CNS during autoimmune inflammation, and finally study the impact of IL-6 on the formation of unique Treg cell niches during recovery from EAE.

Within the upcoming years we will tackle the following questions:

    1. Is continuous sensing of IL-6 required in order to maintain the encephalitogenicity (survival) of Th17 cells?
    2. Can CCR2+ myeloid cells and (to a lesser extent) B cells provide IL-6 signalling?
    3. Can molecules that are suppressed by IL-6 be used as biomarker to predict progressive disease in MS patients?

 

Heink et al., Nat Immunol., 2017

 

Principal Investigators:

Univ.-Prof. Dr. rer. nat. Ari Waisman
Institut für Molekulare Medizin
Mainz
waisman@uni-mainz.de

Univ.-Prof. Dr.med. Thomas Korn
Neurologische Universitätsklinik
TU München
thomas.korn@tum.de

News

Mon, 20/09/2021
Register now: 1st Symposium inflammation and imaging
When?: from November 2nd to November 4th 2021 Where?: Schloss (seat of the University Administration) Muenster Organizers: Co-operative Research Centres 1009, 1450, Transregio 128, and Clinical Research Unit 342 – together with Interdisciplinary Centre of Clinical Research (IZKF) and Excellence Cluster Cells in Motion (CiM) Registration is open now! More information: here...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more